Related Experiment Video
Updated: Jul 19, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma
Silvie Cloosen1, Janwillem Gratama, Ellen B M van Leeuwen
1Department of Internal Medicine, Division of Haematology and Oncology, University Hospital Maastricht, Maastricht, The Netherlands. s.cloosen@immuno.unimaas.nl
Abstract:
Present therapies cannot cure the large majority of patients with multiple myeloma (MM) and therefore new treatment strategies are imperative. This study analysed the different glycosylation profiles of Mucin-1 (MUC1) on MM and acute myeloid leukaemia (AML) cells using a series of anti-MUC1 antibodies. Seventy-three per cent of the MM patients had plasma cells that expressed the fully glycosylated forms of MUC1. In contrast to controls, normal bone marrow cells and AML cells, the differentiation-dependent and cancer-associated glycoforms of MUC1 were present on 59% and 36% MM tumour cells respectively. This indicated that aberrantly glycosylated MUC1 is a potential immunotherapeutic target in MM patients.
Related Concept Videos
Abnormal Proliferation
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Proteoglycans
Mitogens and the Cell Cycle

